«ПРОБЛЕМНЫЕ» ПОЛИРЕЗИСТЕНТНЫЕ БАКТЕРИИ — ВОЗБУДИТЕЛИ ВНУТРИБОЛЬНИЧНЫХ ИНФЕКЦИЙ У ПАЦИЕНТОВ В КРИТИЧЕСКИХ СОСТОЯНИЯХ (ОБЗОР ЛИТЕРАТУРЫ)
Аннотация
РЕЗЮМЕ. Изменение структуры основных возбудителей внутрибольничных инфекций и значительное распространение полирезистентных штаммов бактерий является естественным биологическим ответом на использование антибиотиков. Противомикробные препараты создают селективное давление, способствующее отбору, выживанию и размножению резистентных штаммов. В настоящем обзоре литературы представлена динамика структуры основных возбудителей внутрибольничных гнойносептических инфекций и их устойчивости к антибиотикам за последние 70 лет.
Об авторах
Т. В. ЧерненькаяРоссия
заведующая
научная лаборатория клинической микробиологии
М. А. Годков
Россия
Список литературы
1. Jawetz E., Melnick J.L., Adelberg E.A. Review of medical microbiology. – California: Lange Medical Publications, 1980. – 593 p.
2. Lyon J.A. Imipenem/cilastatin: the first carbapenem antibiotic // Drug. Intell. Clin. Pharm. – 1985. – Vol. 19, N. 12. – P. 895–899.
3. Aznar J., Lepe J.A., Dowzicky M.J. Antimicrobial susceptibility among E. faecalis and E. faecium from France, Germany, Italy, Spain and the UK (T.E.S.T. Surveillance Study, 2004–2009) // J. Chemother. – 2012. – Vol. 24, N. 2. – P. 74–80.
4. Sader H.S., Jones R.N. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007–2008) // Diagn. Microbiol. Infect. Dis. – 2009. – Vol. 65, N. 2. – P. 158–162.
5. Orsini J., Mainardi C., Muzylo E., et al. Microbiological profile of organisms causing bloodstream infection in critically ill patients // J. Clin. Med. Res. – 2012. – Vol. 4, N. 6. – P. 371–377.
6. Caini S., Hajdu A., Kurcz A., Böröcz K. Hospital-acquired infections due to multidrug-resistant organisms in Hungary, 2005–2010 [Электронный ресурс]. – Режим доступа: http://www.eurosurveillance.org/images/ dynamic/EE/V18N02/art20352.pdf
7. Kallen A.J., Mu Y., Bulens S., et al. Health care-associated invasive MRSA infections, 2005–2008 // JAMA. – 2010. – Vol. 304, N. 6. – P. 641–648.
8. Perichon B., Courvalin P. VanA-type vancomycin-resistant Staphylococcus aureus // Antimicrob. Agents Chemother. – 2009. – Vol. 53, N. 11. – P. 4580–4587.
9. Howden B.P., Davies J.K., Johnson P.D., et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications // Clin. Microbiol. Rev. – 2010. – Vol. 23, N. 1. – P. 99–139.
10. Queenan A.M., Bush K. Carbapenemases: the versatile betalactamases // Clin. Microbiol. Rev. – 2007. – Vol. 20, N. 3. – P. 440–458.
11. Hoffken G., Niederman M.S. Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU // Chest. – 2002. – Vol. 122, N. 6. – P. 2183–2196.
12. Marchiam D., Chopra T., Bhargava A., et al. Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship // Infect. Control Hosp. Epidemiol. – 2012. – Vol. 33, N. 8. – P. 817–830.
13. McLaughlin M., Advincula M.R., Malczynski M., et al. Correlations of Antibiotic use and carbapenem resistance in Enterobacteriaceae// Antimicrob. Agents Chemother. – 2013. – Vol. 57, N. 10. – P. 5131–5133.
14. Chaisathaphol T., Chayakulkeeree M. Epidemiology of infections caused by multidrug-resistant gram-negative bacteria in adult hospitalized patients at Siriraj Hospital // J. Med. Assoc. Thai. – 2014. – Vol. 97, Suppl 3. – S35–S45.
15. Lee H.Y., Chen C.L., Wu S.R., et al. Risk factors and outcome analysis of acinetobacter baumannii complex bacteremia in critical patients // Crit. Care Med. – 2014. – Vol. 42, N. 5. – P. 1081–1088.
16. Dizbay M., Guzel Tunccan O., Karasahin O, Aktas F. Emergence of carbapenem-resistant Klebsiella spp. infections in a Turkish university hospital: epidemiology and risk factors // J. Infect. Dev. Ctries. – 2014. – Vol. 8, N. 1. – P. 44–49.
17. Tsai M.H., Chu S.M., Hsu J.F., et al. Risk factors and outcomes for multidrug-resistant Gram-negative bacteremia in the NICU // Pediatrics. – 2014. – Vol. 133, N. 2. – e322–329.
18. Ahn J.Y., Song J.E., Kim M.H., et al. Risk factors for the acquisition of carbapenem-resistant Escherichia coli at a tertiary care center in South Korea: a matched case-control study // Am. J. Infect. Control. – 2014. – Vol. 42, N. 6. – P. 621–625.
19. Kim T., Chong Y.P., Park S.Y., et al. Risk factors for hospital-acquired pneumonia caused by carbapenem-resistant Gram-negative bacteria in critically ill patients: a multicenter study in Korea // Diagn. Microbiol. Infect. Dis. – 2014. – Vol. 78, N. 4. – P. 457–461.
20. Flagas M.E., Karageorgoppoulos D.E. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among gram-negative bacilli: need for international harmonization in terminology // Clin. Infect. Dis. – 2008. – Vol. 46, N. 7. – P. 1121–1122.
21. Giske C.G., Monnet D.L., Cars O., Carmeli Y. Clinical and economic impact of common multidrug-resistant gram-negative bacilli // Antimicrob. Agents Chemother. – 2008. – Vol. 52, N. 3. – P. 813–821.
22. Grundmann H., Livermore D.M., Giske C.G., et al. Carbapenem-nonsusceptible Enterobacteriacae in Europe: conclusions from a meeting of national experts [Электронныйресурс]. – Режим доступа: // www. eurosurveillance.org/ViewArticle.aspx?Articleid=19711
23. Antimicrobial resistance 2010: global attention on carbapenemaseproducing bacteria [Электронныйресурс]. – Режим доступа: http:// eurosurveillance.org/ViewArticle.aspx?ArticleId=19719
24. Souli M., Galani I., Giamarellou H. Emergence of extensively drugresistant and pandrug-resistant gram-negative bacilli in Europe [Электронный ресурс]. – Режим доступа: http://eurosurveillance. org/ViewArticle.aspx?ArticleId=19045
25. Renteria M.I., Biedenbach D.J., Bouchillon S.K., et al. In vitro activity of tigecycline against isolates collected from complicated skin and skin structure infections and intra-abdominal infections in Africa and Middle East countries: TEST 2007–2012 // Diagn. Microbiol. Infect. Dis. – 2014. – Vol. 79, N. 1. – P. 54–59.
26. Behnia M., Logan S.C., Fallen L., Catalano P. Nosocomial and ventilatorassociated pneumonia in a community hospital intensive care unit: a retrospective review and analysis // BMC Res. Notes. – 2014. – Vol. 11, N. 7. – P. 232.
27. Dizbay M., Tunccan O. G., Sezer B. E., et al. Nosocomial Burkholderia cepacia infections in a Turkish university hospital: a five-year surveillance // J. Infect. Dev. Ctries. – 2009. – Vol. 3, N. 4. – P. 273–277.
28. Lee H.G., Jang J., Choi J.E., et al. Blood stream infections in patients in the burn intensive care unit // Infect. Chemother. – 2013. – Vol. 45, N. 2. – P. 194–201.
29. Senbayrak Akcay S., Inan A., Cevan S., et al. Gram-negative bacilli causing infections in an intensive care unit of a tertiary care hospital in Istanbul, Turkey // J. Infect. Dev. Ctries. – 2014. – Vol. 8, N. 5. – P. 597– 604.
30. Wareham D.W., Bean D.C., Khanna P., et al. Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multidrug resistance // Eur. J. Clin. Microbiol. Infect. Dis. – 2008. – Vol. 27, N. 7. – P. 607–612.
31. Xu T., Xia W., Rong G., et al. A 4-year surveillance of antimicrobial resistance patterns of Acinetobacter baumanni in a university-affiliated hospital in China // J. Thorac. Dis. – 2013. – Vol. 5, N. 4. – P. 506–512.
32. Yigit H., Queenan A.M., Anderson G.J., et al. Novel carbapenem-hydrolizing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumonia // Antimicrob. Agents Chemother. – 2001. – Vol. 45, N. 4. – P. 1151–1161.
33. Mantzarlis K., Makris D., Manoulakas E., et al. Risk factors for the first episode of Klebsiella pneumoniae resistant to carbapenemsinfection in critically ill patients: a prospective study // Biomed Res Int. – 2013. – Vol. 2013. – 850547. [Электронный ресурс]. – Режим доступа: http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC3878391/
34. Lucena A., Dalla Costa L.M., Nogueira K.S., et al. Nosocomial infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: molecular epidemiology, risk factors, clinical features and outcomes //J. Hosp. Infect. – 2014. – Vol. 87, N. 4. – P. 234–240.
35. Falagas M.E., Tansarli G.S., Karageorgopoulos D.E., Vardakas K.Z. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections // Emerg. Infect. Dis. – 2014. – Vol. 20, N. 7. – P. 1170–1175.
36. Santoro-Lopes G., de Gouvêa E.F. Multidrug-resistant bacterial infections after liver transplantation: an ever-growing challenge // World J. Gastroenterol. – 2014. – Vol. 20, N. 20. – P. 6201–6210.
37. Kofteridis D.P., Valachis A., Dimopoulou D., et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization: a case-case-control study // J. Infect. Chemother. – 2014. – Vol. 20, N. 5. – P. 293–297.
38. Guidance for control of Infections with carbapenem-resistant or carbapenemase-producing enterobacteriaceae in acute care facilities [Электронныйресурс] // Morb. Mort. Weekly Report (MMWR). – 2009. – Vol. 58, N. 10. – P. 256–260. – Режим доступа: http://www.cdc. gov/mmwr/preview/mmwrhtml/mm5810a4.htm?s_cid=mm5810a4_e
39. Boucher H.W., Talbot G.H., Bradley J.S., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America // Clin. Infect. Dis. – 2009. – Vol. 48, N. 1. – P. 1–12.
40. Bassetti M., Merelli M., Temperoni C., Astilean A. New antibiotics for bad bugs: where are we? [Электронный ресурс] // Ann. Clin. Microbiol. Antimicrob. – 2013. – Vol. 12. – P. 22. – Режим доступа: http://www. ann-clinmicrob.com/content/12/1/22
41. Antimicrobial Resistance [Электронный ресурс]. – Режим доступа: http://www.idsociety.org/10x20/
42. Karaoglan I., Zer Y., Bosnak V.K., et al. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii // J. Int. Med. Res. – 2013. – Vol. 41, N. 6. – P. 1830–1837.
43. Betts J.W., Phee L.M., Hornsey M., et al. In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant enterobacteriaceae // Antimicrob Agents Chemother. – 2014. – Vol. 58, N. 6. – P. 3541–3546.
44. Hagihara M., Housman S.T., Nicolau D.P., Kuti J.L. In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii // Antimicrob. Agents Chemother. – 2014. – Vol. 58, N. 2. – P. 874–879.
45. Zusman O., Avni T., Leibovici L., et al. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems // Antimicrob. Agents Chemother. – 2013. – Vol. 57, N. 10. – P. 5104–5111.
46. Azam A., Ahmed A.S., Oves M., et al. Antimicrobial activity of metal oxide nanoparticles against Gram-positive and Gram-negative bacteria: a comparative study // Int. J. Nanomedicine. – 2012. – Vol. 7. – P. 6003– 6009.
47. Allahverdiyev A.M., Abamor E.S., Bagirova M., Rafailovich M. Antimicrobial effects of TiO(2 ) and Ag(2 )O nanoparticles against drug-resistant bacteria and leishmania parasites// Future Microbiol. – 2011. – Vol. 6, N. 8. – P. 933–940.
48. Fayaz A.M., Balaji K., Girilal M., et al. Biogenic synthesis of silver nanoparticles and their synergistic effect with antibiotics: a study against gram-positive and gram-negative bacteria // Nanomedicine. – 2010. – Vol. 6, N. 1. – P. 103–109.
49. Abedon S.T. Phage therapy: eco-physiological pharmacology [Электронныйресурс] // Scientifica. – 2014. – Vol. 2014, N. 2014. – Article ID 581639. – Режим доступа: http://dx.doi.org/10.1155/2014/581639
50. Cenens W., Makumi A., Mebrhatu M.T., et al. Phage-host interactions during pseudolysogeny: Lessons from the Pid/dgo interaction // Bacteriophage. – 2013. – Vol. 3, N. 1. – e25029.
51. Golkar Z., Bagasra O., Pace D.G. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis // J. Infect. Dev. Ctries. – 2014. – Vol. 8, N. 2. – P. 129–136.
52. Antimicrobial resistance. Fact sheet WHO N194 (Updated April 2014) [Электронный ресурс]. – Режим доступа: http://www.who.int/mediacentre/factsheets/fs194/en/
53. Antimicrobial resistance: global report on surveillance 2014 [Электронный ресурс]. – Режим доступа: http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf
Рецензия
Для цитирования:
Черненькая Т.В., Годков М.А. «ПРОБЛЕМНЫЕ» ПОЛИРЕЗИСТЕНТНЫЕ БАКТЕРИИ — ВОЗБУДИТЕЛИ ВНУТРИБОЛЬНИЧНЫХ ИНФЕКЦИЙ У ПАЦИЕНТОВ В КРИТИЧЕСКИХ СОСТОЯНИЯХ (ОБЗОР ЛИТЕРАТУРЫ). Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь». 2015;(3):30-35.
For citation:
Chernenkaya T.V., Godkov M.A. THE “CHALLENGING” MULTIDRUG-RESISTANT PATHOGENS OF NOSOCOMIAL INFECTIONS IN CRITICALLY ILL PATIENTS (A LITERATURE REVIEW). Russian Sklifosovsky Journal "Emergency Medical Care". 2015;(3):30-35. (In Russ.)